Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CUMBERLAND PHARMACEUTICALS INC (CPIX)

Cumberland Pharmaceuticals Reports Phase 2a Ifetroban Trial Top-Line Results in Systemic Sclerosis

Neutral Impact 3 of 5 product/contract Written later

Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial of oral ifetroban in patients with systemic sclerosis, a rare disease. The company said the results support the drug's safety and tolerability in this population. The filing does not include efficacy data, financial figures, or guidance.

Key points

  • Trial: Phase 2a ASSIST-SSc evaluating oral ifetroban for systemic sclerosis
  • Announced October 23, 2026, with the press release furnished as Exhibit 99.1
  • Company states results support safety and tolerability of ifetroban in this rare disease population
  • Filing contains no financial figures or guidance

The filing

CompanyCUMBERLAND PHARMACEUTICALS INC (CPIX)
Form8-K, current report
Filed with the SECOct 23, 2026, 5:01 PM ET
Accession number0001087294-26-000070

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.